# Evgen Pharma Plc Investor Presentation Year End Mar 31 2017

- Link: https://www.directorstalkinterviews.com/evgen-pharma-plc-investor-presentation-year-end-mar-31-2017/412730792
- Published: 2017-06-26T07:35:19+01:00
- Author: Giles Arbor

**Evgen Pharma Plc** (LON:EVG) CEO Dr Stephen Franklin talks through the Preliminary
Results Presentation for the year ended 31 March 2017.

 

Evgen Pharma Plc is a clinical stage drug development company whose lead programmes
are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also 
carrying out preclinical work in multiple sclerosis and has a clinical interest 
in prostate cancer. The Company’s core technology is Sulforadex®, a method for synthesising
and stabilising the naturally occurring compound sulforaphane and novel proprietary
analogues based on sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.

The company commenced operations in January 2008 and has its headquarters at The
Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science
Park, Liverpool. It joined the AIM market of the London Stock Exchange in October
2015 and trades under the ticker symbol EVG.

Share on:
